About Us QuitPak Catheter Lock Our Team For Investors

A Phase I safety and tolerability clinical trial for QuitPak® has been completed by Dr. Richard Olmstead at the Greater Los Angeles Veterans Affairs Hospital System, an affiliate of UCLA. The trial demonstrated that the product was well tolerated and showed encouraging clinical activity. Development is underway on a sustained-release formulation for QuitPak® that will be used by the Company to conduct its Pharmacokinetics and Phase II clinical trials. Upon the completion of these milestones, Cary Pharma will license QuitPak® to a strategic partner to complete its clinical development through Phase III clinical trials, obtain FDA approval and commercialize the product.

Cary Pharmaceuticals Inc.
9903 Windy Hollow Road
Great Falls, Virginia 22066

Phone: (703) 759-7460